Motif Bio PLC Participation at Upcoming Investor Events

TIDMMTFB

Motif Bio PLC

02 September 2015

2 September 2015

Motif Bio plc

("Motif" or the "Company")

Participation at Upcoming Investor Events

Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that management will participate in three upcoming investor events as outlined below.

The Rodman & Renshaw Annual Global Investment Conference on September 8 through September 10, 2015 at the St. Regis Hotel in New York. Motif will be presenting at 2:10 pm on September 10 in the Louis XVI A room.

BioCentury's 22(nd) Annual NewsMakers in the Biotech Industry conference on September 10, 2015 at the New York City Millennium Broadway Hotel & Conference Center. Motif will be presenting at 10:00 am in room 311.

Ladenburg Thalmann 1st Annual Healthcare Conference on September 29, 2015 at the Sofitel Hotel in New York. Motif will be presenting at 10:30 am in Track 6: the Madeleine Room.

Enquiries

 
 Motif Bio plc                           info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  Robert Bertoldi (Chief Financial 
  Officer) 
  www.motifbio.com 
 
 Zeus Capital Limited (NOMINATED         +44 (0)20 7533 
  ADVISER and BROKER)                     7727 
 Phil Walker/ John Treacy 
  Dominic Wilson 
 Northland Capital Partners Limited      +44 (0) 20 
  (BROKER)                                7382 1100 
 Patrick Claridge/ David Hignell 
  John Howes/ Mark Treharne (Broking) 
 
                                           +49 (0) 89 
                                           210 2280 
  MC Services AG (TRADE                    +44 (0) 207 
    PR)                                    148 5998 
    Raimund Gabriel 
    Shaun Brown 
 
  Plumtree Capital Limited (FINANCIAL      +44 (0) 207 
  ADVISOR)                                 183 2493 
 Stephen Austin 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Dominic Barretto 
  Philip Ranger                          +44 (0) 7768 
  Charles Goodwin                         537 739

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALFFLFATILIIE

(END) Dow Jones Newswires

September 02, 2015 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024